Introduction
Tofacitinib, an oral Janus kinase (JAK) inhibitor, has been increasingly over-scheduled for the treatment of rheumatologic disorders, particularly for challenging rheumatologic conditions that exhibit resistance to conventional treatment regimens.1-2Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome is a rare autoinflammatory disease characterized by osteoarticular and dermatological manifestations, for which there is a lack of standardized treatment. Notably, tofacitinib has demonstrated substantial multidimensional improvements in pain, skin lesions, systemic inflammation, quality of life, and magnetic resonance imaging remission in patients with SAPHO syndrome. Consequently, it is increasingly being employed in refractory SAPHO syndrome cases where biologic therapy has proven ineffective.3-4 However, limited data exist regarding its use during human pregnancies. Here, we report a case of an unintended pregnancy in a patient with SAPHO syndrome who was treated with tofacitinib.